Antibody Engineering: Bispecific antibody platforms

The dual target antibody platform technology of PharmAbcine is based on the fully human antibody candidates selected from HuPhage biopanning process. Depending on antigen presentation patterns on target cell types and the related drug MOA, various bispecific platforms (DIG-body, PIG-body and TIG-body) are adopted in our antibody engineering strategy. PMC-006 (anti-VEGFR2 x anti-Tie2) in our Angiogenesis program, and PMC-122a (anti-PD-L1 x SIRPa) and PMC-122b (anti-PD-L1 x anti-CD47) in Immuno-Oncology program are currently under early development.  




     2F, Research Building 2, 70,

     Yuseong-daero 1689 beon-gil,
     Yuseong-gu, Daejeon, 34047, Republic of Korea


     HQ +82-42-863-2017 

     R&D Center +82-42-861-2017

     Investor Relations +70-4294-6097 

     FAX +82-42-863-2080 


     COPYRIGHT BY PharmAbcine Inc.

     ALL RIGHTS RESERVE